EcoDrugPlus

Free Fatty Acid Receptor 1

Ensembl ID : ENSMAUG00000008356
Gene Symbol: FFAR1
3 Cross references
138 Possible Orthologues:

Free Fatty Acid Receptor 2

Ensembl ID : ENSMAUG00000008579
Gene Symbol: FFAR2
4 Cross references
331 Possible Orthologues:

Fyn Related Src Family Tyrosine Kinase

Ensembl ID : ENSMAUG00000011561
Gene Symbol: FRK
3 Cross references
216 Possible Orthologues:

Galactosidase, Alpha

Ensembl ID : ENSMAUG00000016051
Gene Symbol: GLA
1 Cross references
196 Possible Orthologues:

Galectin 3

Ensembl ID : ENSMAUG00000010860
Gene Symbol: LGALS3
4 Cross references
218 Possible Orthologues:

Gamma-Aminobutyric Acid (Gaba) A Receptor, Pi

Ensembl ID : ENSMAUG00000012765
Gene Symbol: GABRP
1 Cross references
124 Possible Orthologues:

Gamma-Aminobutyric Acid (Gaba) A Receptor, Subunit Alpha 2

Ensembl ID : ENSMAUG00000010408
Gene Symbol: GABRA2
1 Cross references
253 Possible Orthologues:

Gamma-Aminobutyric Acid (Gaba) A Receptor, Subunit Gamma 2

Ensembl ID : ENSMAUG00000019976
Gene Symbol: GABRG2
1 Cross references
204 Possible Orthologues:

Gamma-Aminobutyric Acid (Gaba) B Receptor, 2

Ensembl ID : ENSMAUG00000007099
Gene Symbol: GABBR2
1 Cross references
241 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Alpha1

Ensembl ID : ENSMAUG00000018769
Gene Symbol: GABRA1
4 Cross references
202 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Alpha3

Ensembl ID : ENSMAUG00000008354
Gene Symbol: GABRA3
4 Cross references
198 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Alpha4

Ensembl ID : ENSMAUG00000021317
Gene Symbol: GABRA4
4 Cross references
201 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).